TrialSignal
Clinical trial intelligence report
A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03318861-Jul 28, 2026
NCT ID
NCT03318861
Status
TERMINATED
Phase
Phase 1
Sponsor
Kite, A Gilead Company
Executive brief
Investment-Ready Snapshot
KITE-585, an autologous anti-BCMA CAR T-cell therapy developed by Kite, a Gilead Company, targets relapsed/refractory multiple myeloma. The therapy's development was aimed at addressing a significant unmet need in a market characterized by high competition from other CAR T-cell therapies and novel agents. The termination of the study due to lack of efficacy raises concerns regarding the commercial viability of KITE-585, which may impact Kite's strategic positioning in the CAR T-cell landscape. This outcome necessitates a thorough evaluation of alternative therapies and potential partnerships to bolster Kite's pipeline.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03318861
Indication
Relapsed/Refractory Multiple Myeloma
Modality
gene therapy
Target
B-cell maturation antigen (BCMA)
Intervention
KITE-585, Cyclophosphamide, Fludarabine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.